Flow cytometric analysis of fixed and permeabilized A-204 cells using FGF Receptor 1 (D8E4) XP® Rabbit mAb (blue) compared to concentration-matched Rabbit (DA1E) mAb IgG XP® Isotype Control #3900 (red). Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) #4412 was used as a secondary antibody.
Confocal immunofluorescent analysis of serum-starved A-204 cells, untreated (left), treated with heparin (1 μg/mL, 5 min) followed by the addition of Human Basic Fibroblast Growth Factor (hFGF basic/FGF2) #61977 (100 ng/mL, 5 min; center), or treated with heparin/FGF2 and post-processed with λ-phosphatase (2 hr; right), using Phospho-FGF Receptor 1 (Tyr653/654) (D4X3D) Rabbit mAb (upper, green) and FGF Receptor 1 (D8E4) XP® Rabbit mAb #9740 (lower, green). Samples were mounted in ProLong® Gold Antifade Reagent with DAPI #8961 (blue).
Confocal immunofluorescent analysis of A204 cells (positive, left), KG-1 cells (positive, middle) and A172 cells (weak expression, right) using FGF Receptor 1 (D8E4) XP® Rabbit mAb (green). Blue pseudocolor= DRAQ5® #4084 (fluorescent DNA dye).
Immunoprecipitation of Phospho-FGF receptor 1 (Tyr653/654) protein from A-204 cell treated with heparin (1 μg/mL, 5 min) followed by the Human Basic Fibroblast Growth Factor (hFGF basic/FGF2) #61977 (100 ng/mL, 5 min). Lane 1 is 10% input, lane 2 is Rabbit (DA1E) mAb IgG XP® Isotype Control #3900, and lane 3 is Phospho-FGF Receptor 1(Tyr653/654) (D4X3D) Rabbit mAb. Western blot analysis was performed using Phospho-FGF Receptor 1(Tyr653/654) (D4X3D) Rabbit mAb as primary antibody. Anti-rabbit IgG, HRP-linked Antibody #7074 was used as secondary antibody.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using FGF Receptor 1 (D8E4) XP® Rabbit mAb.
Western blot analysis of extracts from A-204 cells, untreated (-) or treated with heparin (1 μg/mL, 5 min) followed by the Human Basic Fibroblast Growth Factor (hFGF basic/FGF2) #61977 (100 ng/mL, 5 min, +), using Phospho-FGF Receptor 1 (Tyr653/654) (D4X3D) Rabbit mAb (upper) and FGF Receptor 1 (D8E4) XP® Rabbit mAb #9740 (lower).
Immunohistochemical analysis of paraffin-embedded human kidney using FGF Receptor 1 (D8E4) XP® Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human lung carcinoma using FGF Receptor 1 (D8E4) XP® Rabbit mAb.
Western blot analysis of extracts from A-204 (FGFR1 positive), KG-1a (FGFR1 oncogenic partner-FGFR1 fusion), A172 (FGFR1 low), and HT-29 (FGFR1 negative) cells using FGF Receptor 1 (D8E4) XP® Rabbit mAb (upper) and β-Actin (D6A8) Rabbit mAb #8457 (lower).
|FGF Receptor 1 (D8E4) XP® Rabbit mAb 9740||100 µl||H Mk M R||92 , 120, 145||Rabbit IgG|
|Phospho-FGF Receptor 1 (Tyr653/654) (D4X3D) Rabbit mAb 52928||100 µl||H||120, 145||Rabbit IgG|
PhosphoPlus® Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.
Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic kinase domain (1). Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues (2). Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling (3). The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCγ (4,5).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.